-
1دورية أكاديمية
المؤلفون: L. A. Shpagina, О. S. Kotova, I. S. Shpagin, Е. М. Loktin, G. V. Kuznetsova, S. A. Karmanovskaya, L. A. Panacheva, E. V. Anikina
المصدر: Сибирский научный медицинский журнал, Vol 44, Iss 2, Pp 137-148 (2024)
مصطلحات موضوعية: chronic obstructive pulmonary disease exacerbation, respiratory viral infection, n-terminal propeptide of type iii procollagen, granulocyte-macrophage colony-stimulating factor, Medicine
وصف الملف: electronic resource
العلاقة: https://sibmed.elpub.ru/jour/article/view/1470Test; https://doaj.org/toc/2410-2512Test; https://doaj.org/toc/2410-2520Test
-
2دورية أكاديمية
المؤلفون: L. A. Shpagina, O. S. Kotova, I. S. Shpagin, E. M. Loktin, A. A. Rukavitsyna, T. S. Flyagin, T. M. Smarzh, N. V. Kamneva, D. A. Gerasimenko, E. V. Anikina, A. V. Ponomareva
المصدر: Российский кардиологический журнал, Vol 25, Iss 5 (2020)
مصطلحات موضوعية: direct oral anticoagulants, bleeding, idarucizumab, Diseases of the circulatory (Cardiovascular) system, RC666-701
وصف الملف: electronic resource
العلاقة: https://russjcardiol.elpub.ru/jour/article/view/3921Test; https://doaj.org/toc/1560-4071Test; https://doaj.org/toc/2618-7620Test
-
3دورية أكاديمية
المؤلفون: V. L. Yakovlev, E. V. Anikina, I. A. Kozlova, S. V. Kornilkov
المصدر: Литосфера, Vol 0, Iss 2, Pp 337-339 (2019)
مصطلحات موضوعية: Engineering geology. Rock mechanics. Soil mechanics. Underground construction, TA703-712
وصف الملف: electronic resource
العلاقة: https://www.lithosphere.ru/jour/article/view/1167Test; https://doaj.org/toc/1681-9004Test; https://doaj.org/toc/2500-302XTest
-
4دورية أكاديمية
المؤلفون: L. A. Shpagina, O. S. Kotova, I. S. Shpagin, G. V. Kuznetsova, S. A. Karmanovskaya, L. A. Panacheva, E. V. Anikina, Л. А. Шпагина, О. С. Котова, И. С. Шпагин, Г. В. Кузнецова, С. А. Кармановская, Л. А. Паначева, Е. В. Аникина
المساهمون: Federal budget funds for the implementation of state task No.056-00034-21-00 were used, Исследование осуществлялось за счет средств федерального бюджета на исполнение государственного задания № 05600034-21-00
المصدر: PULMONOLOGIYA; Том 33, № 6 (2023); 739-749 ; Пульмонология; Том 33, № 6 (2023); 739-749 ; 2541-9617 ; 0869-0189
مصطلحات موضوعية: длительно действующие антихолинергические препараты, exacerbation, respiratory viral infection, inhaled corticosteroid, long-acting β2-agonist, longacting muscarinic antagonist, обострение, респираторная вирусная инфекция, ингаляционные глюко-кортикостероиды, длительно действующие β2-агонисты
وصف الملف: application/pdf
العلاقة: https://journal.pulmonology.ru/pulm/article/view/4372/3578Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2183Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2184Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2185Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2186Test; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4372/2187Test; GBD 2019 Chronic Respiratory Diseases Collaborators. Global burden of chronic respiratory diseases and risk factors, 1990-2019: an update from the global burden of disease study 2019. EClinicalMedicine. 2023; 59: 101936. DOI:10.1016/j.eclinm.2023.101936.; Федеральная служба государственной статистики (Росстат). Российский статистический ежегодник: статистический сборник. М; 2022. Доступно на: https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2022.pdfTest; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 963–974. DOI:10.2147/COPD.S67283.; Быстрицкая Е.В., Биличенко Т.Н. Заболеваемость, инвалидность и смертность от болезней органов дыхания в Российской Федерации (2015–2019). Пульмонология. 2021; 31 (5): 551–561. DOI:10.18093/0869-0189-2021-31-5-551-561.; Brightling C., Greening N. Airway inflammation in COPD: progress to precision medicine. Eur. Respir. J. 2019; 54 (2): 1900651. DOI:10.1183/13993003.00651-2019.; Шпагина Л.А., Котова О.С., Сараскина Л.Е., Ермакова М.А. Особенности клеточно-молекулярных механизмов профессиональной хронической обструктивной болезни легких. Сибирское медицинское обозрение. 2018; 110 (2): 37–45. DOI:10.20333/2500136-2018-2-37-45.; Wu J.J., Xu H.R., Zhang Y.X. et al. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review. BMC Pulm. Med. 2020; 20 (1): 103. DOI:10.1186/s12890-020-1126-x.; Зыков К.А., Овчаренко С.И., Авдеев С.Н. и др. Фенотипические характеристики пациентов с хронической обструктивной болезнью легких, имеющих стаж курения, в Российской Федерации: данные исследования POPE-study. Пульмонология. 2020; 30 (1): 42–52. DOI:10.18093/0869-0189-2020-30-1-42-52.; Müllerová H., Marshall J., de Nigris E. et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Adv. Respir. Dis. 2022; 16: 17534666221113647. DOI:10.1177/17534666221113647.; Ghebre M.A., Pang P.H., Diver S. et al. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. J. Allergy Clin. Immunol. 2018; 141 (6): 2027–2036.e12. DOI:10.1016/j.jaci.2018.04.013.; Hurst J.R., Han M.K., Singh B. et al. Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review. Respir. Res. 2022; 23 (1): 213. DOI:10.1186/s12931-022-02123-5.; Visseaux B., Burdet C., Voiriot G. et al. Prevalence of respiratory viruses among adults, by season, age, respiratory tract region and type of medical unit in Paris, France, from 2011 to 2016. PLoS One. 2017; 12 (7): e0180888. DOI:10.1371/journal.pone.0180888.; Jafarinejad H., Moghoofei M., Mostafaei S. et al. Worldwide prevalence of viral infection in AECOPD patients: a meta-analysis. Microb. Pathog. 2017; 113: 190–196. DOI:10.1016/j.micpath.2017.10.021.; Liao K.M., Chen Y.J., Shen C.W. et al. The influence of influenza virus infections in patients with chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2022; 17: 2253–2261. DOI:10.2147/COPD.S378034.; Mahmud S.M.H., Al-Mustanjid M., Akter F. et al. Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients. Brief. Bioinform. 2021; 22 (5): bbab115. DOI:10.1093/bib/bbab115.; Guo-Parke H., Linden D., Weldon S. et al. Mechanisms of virus-induced airway immunity dysfunction in the pathogenesis of COPD disease, progression, and exacerbation. Front. Immunol. 2020; 11: 1205. DOI:10.3389/fimmu.2020.01205.; D'Anna S.E., Maniscalco M., Cappello F. et al. Bacterial and viral infections and related inflammatory responses in chronic obstructive pulmonary disease. Ann. Med. 2021; 53 (1): 135–150. DOI:10.1080/07853890.2020.1831050.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022; 32 (3): 356–392. DOI:10.18093/0869-0189-2022-32-3-356-392.; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Prevention, Diagnosis and Management of COPD: 2023 COLD Report. Available at: https://goldcopd.org/2023-gold-report-2Test/ [Assecced: August 04, 2023].; Авдеев С.Н., Айсанов З.Р., Архипов В.В. и др. Назначение / отмена ингаляционных глюкокортикостероидов у больных хронической обструктивной болезнью легких как терапевтический континуум в реальной клинической практике. Пульмонология. 2023; 33 (1): 109–118. DOI:10.18093/0869-0189-2023-33-1-109-118.; Alcázar-Navarrete B, Jamart L, Sánchez-Covisa J. et al. Clinical characteristics, treatment persistence, and outcomes among patients with COPD treated with single- or multiple-inhaler triple therapy: a retrospective analysis in Spain. Chest. 2022; 162 (5): 1017–1029. DOI:10.1016/j.chest.2022.06.033.; Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 648–654. DOI:10.1183/09031936.00102509.; Чучалин А.Г., Айсанов З.Р., Чикина С.Ю. и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014; (6): 11–24. DOI:10.18093/0869-0189-2014-0-6-11-24.; Graham B.L., Brusasco V., Burgos F. et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur. Respir. J. 2017; 49 (1): 1600016. DOI:10.1183/13993003.00016-2016.; ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166 (1): 111–117. DOI:10.1164/ajrccm.166.1.at1102.; Puhan M.A., Chandra D., Mosenifar Z. et al. The minimal important difference of exercise tests in severe COPD. Eur. Respir. J. 2011; 37 (4): 784–790. DOI:10.1183/09031936.00063810.; Шпагина Л.А., Котова О.С., Шпагин И.С. и др. Клинико-функциональные особенности хронической обструктивной болезни легких после вирус-ассоциированных обострений. Терапевтический архив. 2023; 95 (3): 217–222. DOI:10.26442/00403660.2023.03.202086.; Singh D., Papi A., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016; 388 (10048): 963–973. DOI:10.1016/s0140-6736(16)31354-x.; Lipson D.A., Barnhart F., Brealey N. et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N. Engl. J. Med. 2018; 378 (18): 1671–1680. DOI:10.1056/NEJMoa1713901.; Ferguson G.T., Rabe K.F., Martinez F.J. et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir. Med. 2018; 6 (10): 747–758. DOI:10.1016/S2213-2600(18)30327-8.; Halpin D.M.G., Kendall R., Shukla S. et al. Cost-effectiveness of single- versus multiple-inhaler triple therapy in a UK COPD population: the INTREPID trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2022; 17: 2745–2755. DOI:10.2147/COPD.S370577.; Ferguson G.T., Brown N., Compton C. et al. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials. Respir. Res. 2020; 21 (1): 131. DOI:10.1186/s12931-020-01360-w.; David B., Bafadhel M., Koenderman L., De Soyza A. Eosinophilic inflammation in COPD: from an inflammatory marker to a treatable trait. Thorax. 2021; 76 (2): 188–195. DOI:10.1136/thoraxjnl-2020-215167.; Насонов Е.Л., ред. Российские клинические рекомендации: Ревматология. М.: ГЭОТАР-Медиа; 2020.; De Sadeleer L.J., Hermans F., De Dycker E. et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J. Clin. Med. 2018; 8 (1): 14. DOI:10.3390/jcm8010014.; RECOVERY Collaborative Group; Horby P., Lim W.S. et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021; 384 (8): 693–704. DOI:10.1056/NEJMoa2021436.; Ponce-Gallegos M.A., Ramírez-Venegas A., Falfán-Valencia R. Th17 profile in COPD exacerbations. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; 12: 1857–1865. DOI:10.2147/COPD.S136592.; Su Y., Gu H., Weng D. et al. Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease. Medicine (Baltimore). 2017; 96 (18): e6617. DOI:10.1097/MD.0000000000006617.; https://journal.pulmonology.ru/pulm/article/view/4372Test
الإتاحة: https://doi.org/10.18093/0869-0189-2023-33-6-739-749Test
https://doi.org/10.1016/j.eclinm.2023.101936Test
https://doi.org/10.2147/COPD.S67283Test
https://doi.org/10.18093/0869-0189-2021-31-5-551-561Test
https://doi.org/10.1183/13993003.00651-2019Test
https://doi.org/10.20333/2500136-2018-2-37-45Test
https://doi.org/10.1186/s12890-020-1126-xTest
https://doi.org/10.18093/0869-0189-2020-30-1-42-52Test
https://doi.org/10.1177/17534666221113647Test
https://doi.org/10.1016/j.jaci.2018.04.013Test -
5دورية أكاديمية
المؤلفون: L. A. Shpagina, O. S. Kotova, I. S. Shpagin, G. V. Kuznetsova, D. A. Gerasimenko, E. V. Anikina, Л. А. Шпагина, О. С. Котова, И. С. Шпагин, Г. В. Кузнецова, Д. А. Герасименко, Е. В. Аникина
المساهمون: The study was conducted at the expense of the federal budget according to the state assignment 056-00034-21-00., Исследование проводилось на средства федерального бюджета на исполнение государственного задания № 056-0003421-00.
المصدر: PULMONOLOGIYA; Том 32, № 2 (2022); 189-198 ; Пульмонология; Том 32, № 2 (2022); 189-198 ; 2541-9617 ; 0869-0189
وصف الملف: application/pdf
العلاقة: https://journal.pulmonology.ru/pulm/article/view/3850/3197Test; Adeloye D., Chua S., Lee C. et al. Global Health Epidemiology Reference Group (GHERG). Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J. Glob. Health. 2015; 5 (2): 020415. DOI:10.7189/jogh.05-020415.; Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. Chron. Obstruct. Pulmon. Dis. 2014; 9: 963–974. DOI:10.2147/COPD.S67283.; INME. GBD Compare %7C Viz Hub. Available at: https://vizhub.healthdata.org/gbd-compareTest/ [Assecced: July 13, 2021].; Gerayeli FV, Milne S, Cheung C. et al. COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine. 2021; 33: 100789. DOI:10.1016/j.eclinm.2021.100789.; Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2021 Report. Available at: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdfTest [Assessed: July 13, 2021].; Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 27 (1): 13–20. DOI:10.18093/0869-0189-2017-27-1-13-20.; Suissa S., Dell’Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67 (11): 957–963. DOI:10.1136/thoraxjnl-2011-201518.; Naya I.P., Tombs L., Muellerova H. et al. Long-term outcomes following first short-term clinically important deterioration in COPD. Respir. Res. 2018; 19 (1): 222. DOI:10.1186/s12931-018-0928-3.; Kerkhof M., Voorham J., Dorinsky P. et al. Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax. 2020; 75 (9): 744–753. DOI:10.1136/thoraxjnl-2019-214457.; Sato M., Chubachi S., Sasaki M. et al. Impact of mild exacerbation on COPD symptoms in a Japanese cohort. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11: 1269–1278. DOI:10.2147/COPD.S105454.; Westerik J.A.M., Metting E.I., van Boven J.F.M. et al. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir. Res. 2017; 18 (1): 31. DOI:10.1186/s12931-017-0512-2.; Зыков К.А., Овчаренко С.И., Авдеев С.Н. и др. Фенотипические характеристики пациентов с хронической обструктивной болезнью легких, имеющих стаж курения, в Российской Федерации: данные исследования POPE-study. Пульмонология. 2020; 30 (1): 42–52. DOI:10.18093/0869-0189-2020-30-1-42-52.; Со А.К., Авдеев С.Н., Нуралиева Г.С. и др. Предикторы неблагоприятного исхода при обострении хронической обструктивной болезни легких. Пульмонология. 2018; 28 (4): 446–452. DOI:10.18093/0869-0189-2018-28-4-446-452.; Luo Z., Zhang W., Chen L., Xu N. Prognostic value of neutrophil: lymphocyte and platelet: Lymphocyte ratios for 28-day mortality of patients with AECOPD. Int. J. Gen. Med. 2021; 14: 2839–2848. DOI:10.2147/IJGM.S312045.; Crisafulli E., Ielpo A., Barbeta E. et al. Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. Respir. Res. 2018; 19 (1): 261. DOI:10.1186/s12931-018-0951-4.; Brandsma C.A., Van den Berge M., Hackett T.L. et al. Recent advances in chronic obstructive pulmonary disease pathogenesis: from disease mechanisms to precision medicine. J. Pathol. 2020; 250 (5): 624–635. DOI:10.1002/path.5364.; Jones T.P.W., Brown J., Hurst J.R. et al. COPD exacerbation phenotypes in a real-world five year hospitalisation cohort. Respir. Med. 2020; 167: 105979. DOI:10.1016/j.rmed.2020.105979.; Jafarinejad H., Moghoofei M., Mostafaei S. et al. Worldwide prevalence of viral infection in AECOPD patients: a meta-analysis. Microb. Pathog. 2017; 113: 190–196. DOI:10.1016/j.micpath.2017.10.021.; Jones P.W., Harding G., Berry P. et al. Development and first validation of the COPD Assessment Test. Eur. Respir. J. 2009; 34 (3): 648–654. DOI:10.1183/09031936.00102509.; Чучалин А.Г., Айсанов З.Р., Чикина С.Ю. и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология. 2014; (6): 11–24. DOI:10.18093/0869-0189-2014-0-6-11-24.; Graham B.L., Brusasco V., Burgos F. et al. 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur. Respir. J. 2017; 49 (1): 1600016. DOI:10.1183/13993003.00016-2016.; Pavord I.D., Lettis S., Anzueto A., Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir. Med. 2016; 4 (9): 731–741. DOI:10.1016/S2213-2600(16)30148-5.; Haldar P., Pavord I.D. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J. Allergy Clin. Immunol. 2007; 119 (5): 1043–1052. DOI:10.1016/j.jaci.2007.02.042.; Gunasekaran K., Ahmad M., Rehman S. et al. Impact of a positive viral polymerase chain reaction on outcomes of chronic obstructive pulmonary disease (COPD) exacerbations. Int. J. Environ. Res. Public. Health. 2020; 17 (21): 8072. DOI:10.3390/ijerph17218072.; Wilkinson T.M.A., Hurst J.R., Perera W.R. et al. Eff of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006; 129 (2): 317–324. DOI:10.1378/chest.129.2.317.; Шпагина Л.А., Котова О.С., Сараскина Л.Е., Ермакова М.А. Особенности клеточно-молекулярных механизмов профессиональной хронической обструктивной болезни легких. Сибирское медицинское обозрение. 2018; 110 (2): 37–45. DOI:10.20333/2500136-2018-2-37-45.; Fonseca W., Lukacs N.W., Elesela S., Malinczak C.A. Role of ILC2 in viral-induced lung pathogenesis. Front. Immunol. 2021; 12: 675169. DOI:10.3389/fimmu.2021.675169.; Wronski S., Beinke S., Obernolte H. et al. Rhinovirus-induced human lung tissue responses mimic COPD and asthma gene signatures. Am. J. Respir. Cell. Mol. Biol. 2021: 65 (5): 544–554. DOI:10.1165/rcmb.2020-0337OC.; Jang J.G., Ahn J.H., Jin H.J. Incidence and prognostic factors of respiratory viral infections in severe acute exacerbation of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2021; 16: 1265–1273. DOI:10.2147/COPD.S306916.; https://journal.pulmonology.ru/pulm/article/view/3850Test
الإتاحة: https://doi.org/10.18093/0869-0189-2022-32-2-189-198Test
https://doi.org/10.7189/jogh.05-020415Test
https://doi.org/10.2147/COPD.S67283Test
https://doi.org/10.1016/j.eclinm.2021.100789Test
https://doi.org/10.18093/0869-0189-2017-27-1-13-20Test
https://doi.org/10.1136/thoraxjnl-2011-201518Test
https://doi.org/10.1186/s12931-018-0928-3Test
https://doi.org/10.1136/thoraxjnl-2019-214457Test
https://doi.org/10.2147/COPD.S105454Test
https://doi.org/10.1186/s12931-017-0512-2Test -
6دورية أكاديمية
المؤلفون: L. A. Shpagina, O. S. Kotova, I. S. Shpagin, D. A. Gerasimenko, G. V. Kuznetsova, S. A. Karmanovskaya, E. M. Loktin, A. A. Rukavitsyna, E. V. Anikina, N. V. Kamneva, K. V. Likhenko-Logvinenko, Л. А. Шпагина, О. С. Котова, И. С. Шпагин, Д. А. Герасименко, Г. В. Кузнецова, С. А. Кармановская, Е. М. Локтин, А. А. Рукавицына, Е. В. Аникина, Н. В. Камнева, К. В. Лихенко-Логвиненко
المساهمون: The article was written within the framework of the state assignment 056-00034-21-00, Статья написана в рамках государственного задания 056-00034-21-00
المصدر: Meditsinskiy sovet = Medical Council; № 18 (2022); 30-39 ; Медицинский Совет; № 18 (2022); 30-39 ; 2658-5790 ; 2079-701X
مصطلحات موضوعية: фиброз, acute exacerbations of chronic obstructive pulmonary disease, respiratory viruses, inflammation, fibrosis, обострение хронической обструктивной болезни легких, респираторные вирусы, воспаление
وصف الملف: application/pdf
العلاقة: https://www.med-sovet.pro/jour/article/view/7117/6389Test; MacDonald M.I., Osadnik C.R., Bulfin L., Leahy E., Leong P., Shafuddin E. et al. MULTI-PHACET: multidimensional clinical phenotyping of hospitalised acute COPD exacerbations. ERJ Open Res. 2021;7(3):00198–2021. https://doi.org/10.1183/23120541.00198-2021Test.; Jafarinejad H., Moghoofei M., Mostafaei S., Salimian J., Azimzadeh Jamalkandi S., Ahmadi A. Worldwide prevalence of viral infection in AECOPD patients: A meta-analysis. Microb Pathog. 2017;113:190–196. https://doi.org/10.1016/j.micpath.2017.10.021Test.; Jang J.G., Ahn J.H., Jin H.J. Incidence and prognostic factors of respiratory viral infections in severe acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2021;16:1265–1273. https://doi.org/10.2147/COPD.S306916Test.; Lee H.W., Sim Y.S., Jung J.Y., Seo H., Park J.W., Min K.H. et al. A multicenter study to identify the respiratory pathogens associated with exacerbation of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis (Seoul). 2022;85(1):37–46. https://doi.org/10.4046/trd.2021.0080Test.; Polverino F., Kheradmand F. COVID-19, COPD, and AECOPD: Immunological, epidemiological, and clinical aspects. Front Med (Lausanne). 2021;7:627278. https://doi.org/10.3389/fmed.2020.627278Test.; Huebner S.T., Henny S., Giezendanner S., Brack T., Brutsche M., Chhajed P. et al. Prediction of acute COPD exacerbation in the Swiss multicenter COPD cohort study (TOPDOCS) by clinical parameters, medication use, and immunological biomarkers. Respiration. 2022;101(5):441–454. https://doi.org/10.1159/000520196Test.; Suissa S., Dell’Aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963. https://doi.org/10.1136/thoraxjnl-2011-201518Test.; Зыков К.А., Овчаренко С.И., Авдеев С.Н., Жестков А.В., Илькович М.М., Невзорова В.А. и др. Фенотипические характеристики пациентов с хронической обструктивной болезнью легких, имеющих стаж курения, в Российской Федерации: данные исследования POPE-study. Пульмонология. 2020;30(1):42–52. https://doi.org/10.18093/0869-0189-2020-30-1-42-52Test.; Rhodes K., Jenkins M., de Nigris E., Aurivillius M., Ouwens M. Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study. BMC Med Res Methodol. 2022;22(1):150. https://doi.org/10.1186/s12874-022-01616-7Test.; Со А.К., Авдеев С.Н., Нуралиева Г.С., Гайнитдинова В.В., Чучалин А.Г. Предикторы неблагоприятного исхода при обострении хронической обструктивной болезни легких. Пульмонология. 2018;28(4):446–452. https://doi.org/10.18093/0869-0189-2018-28-4-446-452Test.; Luo Z., Zhang W., Chen L., Xu N. Prognostic Value of Neutrophil:Lymphocyte and Platelet:Lymphocyte Ratios for 28-Day Mortality of Patients with AECOPD. Int J Gen Med. 2021;14:2839–2848. https://doi.org/10.2147/IJGM.S312045Test.; Cao Y., Xing Z., Long H., Huang Y., Zeng P., Janssens J.P., Guo Y. Predictors of mortality in COPD exacerbation cases presenting to the respiratory intensive care unit. Respir Res. 2021;22(1):77. https://doi.org/10.1186/s12931-021-01657-4Test.; Быстрицкая Е.В., Биличенко Т.Н. Заболеваемость, инвалидность и смертность от болезней органов дыхания в Российской Федерации (2015–2019). Пульмонология. 2021;31(5):551–561. https://doi.org/10.18093/0869-0189-2021-31-5-551-561Test.; Jones T.P.W., Brown J., Hurst J.R., Vancheeswaran R., Brill S. COPD exacerbation phenotypes in a real-world five year hospitalisation cohort. Respir Med. 2020;167:105979. https://doi.org/10.1016/j.rmed.2020.105979Test.; Ritchie A.I., Wedzicha J.A. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41(3):421–438. https://doi.org/10.1016/j.ccm.2020.06.007Test.; Li T., Gao L., Ma H.X., Wei Y.Y., Liu Y.H., Qin K.R. et al. Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients. Exp Biol Med (Maywood). 2020;245(14):1290–1298. https://doi.org/10.1177/1535370220931765Test.; Ji S., Dai M.Y., Huang Y., Ren X.C., Jiang M.L., Qiao J.P. et al. Influenza a virus triggers acute exacerbation of chronic obstructive pulmonary disease by increasing proinflammatory cytokines secretion via NLRP3 inflammasome activation. J Inflamm (Lond). 2022;19(1):8. https://doi.org/10.1186/s12950-022-00305-yTest.; Wronski S., Beinke S., Obernolte H., Belyaev N.N., Saunders K.A., Lennon M.G. et al. Rhinovirus-induced human lung tissue responses mimic chronic obstructive pulmonary disease and asthma gene signatures. Am J Respir Cell Mol Biol. 2021;65(5):544–554. https://doi.org/10.1165/rcmb.2020-0337OCTest.; Thulborn S.J., Mistry V., Brightling C.E., Moffitt K.L., Ribeiro D., Bafadhel M. Neutrophil elastase as a biomarker for bacterial infection in COPD. Respir Res. 2019;20(1):170. https://doi.org/10.1186/s12931-019-1145-4Test.; Chakrabarti A., Mar J.S., Choy D.F., Cao Y., Rathore N., Yang X. et al. High serum granulocyte-colony stimulating factor characterises neutrophilic COPD exacerbations associated with dysbiosis. ERJ Open Res. 2021;7(3):00836–2020. https://doi.org/10.1183/23120541.00836-2020Test.; Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Лещенко И.В., Овчаренко С.И., Шмелев Е.И. Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):356–392. https://doi.org/10.18093/0869-0189-2022-32-3-356-392Test.; Weissler J.C., Adams T.N. Eosinophilic chronic obstructive pulmonary disease. Lung. 2021;199(6):589–595. https://doi.org/10.1007/s00408-021-00492-0Test.; Chen X.R., Wang D.X. Serum MCP-1 and NGAL play an important role in the acute inflammatory event of chronic obstructive pulmonary disease. COPD. 2021;18(4):425–431. https://doi.org/10.1080/15412555.2021.1954151Test.; Chanda D., Otoupalova E., Smith S.R., Volckaert T., De Langhe S.P., Thannickal V.J. Developmental pathways in the pathogenesis of lung fibrosis. Mol Aspects Med. 2019;65:56–69. https://doi.org/10.1016/j.mam.2018.08.004Test.; Zhang Y., Li Y., Ye Z., Ma H. Expression of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and changes in alveolar septa in patients with chronic obstructive pulmonary disease. Med Sci Monit. 2020;26:e925278. https://doi.org/10.12659/MSM.925278Test.; Johansen M.D., Mahbub R.M., Idrees S., Nguyen D.H., Miemczyk S., Pathinayake P. et al. Increased SARS-CoV-2 infection, protease and inflammatory responses in COPD primary bronchial epithelial cells defined with single cell RNA-sequencing. Am J Respir Crit Care Med. 2022. https://doi.org/10.1164/rccm.202108-1901OCTest.; Baldi B.G., Fabro A.T., Franco A.C., Machado M.H.C., Prudente R.A., Franco E.T. et al. Clinical, radiological, and transbronchial biopsy findings in patients with long COVID-19: a case series. J Bras Pneumol. 2022;48(3):e20210438. https://doi.org/10.36416/1806-3756/e20210438Test.; Bafadhel M., Peterson S., De Blas M.A., Calverley P.M., Rennard S.I., Richter K., Fagerås M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6(2):117–126. https://doi.org/10.1016/S2213-2600Test(18)30006-7.; Rana R., Huang T., Koukos G., Fletcher E.K., Turner S.E., Shearer A. et al. Noncanonical matrix metalloprotease 1-protease-activated receptor 1 signaling drives progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 2018;38(6):1368–1380. https://doi.org/10.1161/ATVBAHA.118.310967Test.; https://www.med-sovet.pro/jour/article/view/7117Test
الإتاحة: https://doi.org/10.21518/2079-701X-2022-16-18-30-39Test
https://doi.org/10.1183/23120541.00198-2021Test
https://doi.org/10.1016/j.micpath.2017.10.021Test
https://doi.org/10.2147/COPD.S306916Test
https://doi.org/10.4046/trd.2021.0080Test
https://doi.org/10.3389/fmed.2020.627278Test
https://doi.org/10.1159/000520196Test
https://doi.org/10.1136/thoraxjnl-2011-201518Test
https://doi.org/10.18093/0869-0189-2020-30-1-42-52Test
https://doi.org/10.1186/s12874-022-01616-7Test -
7
المؤلفون: V. A. Poklonov, V. V. Glebov, D. A. Askarova, V. V. Erofeeva, E. V. Anikina
المصدر: Russian Journal of General Chemistry. 91:2908-2916
مصطلحات موضوعية: General Chemistry
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::6c7d6c2b4a432279897e6abba666bd65Test
https://doi.org/10.1134/s1070363221130193Test -
8دورية أكاديمية
المؤلفون: E V Anikina
المصدر: RUDN Journal of Ecology and Life Safety, Vol 0, Iss 2, Pp 44-48 (2011)
مصطلحات موضوعية: ecological and social factors, a megacity, foreign students, health, smoking, alcoholism, psychotropic substances, Environmental sciences, GE1-350
وصف الملف: electronic resource
-
9دورية أكاديمية
المؤلفون: E V Anikina
المصدر: RUDN Journal of Ecology and Life Safety, Vol 0, Iss S5, Pp 11-13 (2012)
مصطلحات موضوعية: african students, environment, factors, adaptable process, high school education, motivation, pedagogical system, psychological features, megalopolis, Environmental sciences, GE1-350
وصف الملف: electronic resource
-
10
المؤلفون: D A Gerasimenko, G V Kuznetsova, L. Shpagina, E V Anikina, I. Shpagin, N V Kamneva, O. Kotova
المصدر: European Heart Journal. 41
مصطلحات موضوعية: Spirometry, medicine.medical_specialty, medicine.diagnostic_test, business.industry, medicine.disease, Brain natriuretic peptide, Comorbidity, Heart failure, Internal medicine, Epidemiology, Medicine, Decompensation, Cardiology and Cardiovascular Medicine, business, Heart failure with preserved ejection fraction, Survival analysis
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::1b80fc6827606fbcfbc46b5be3c95fb5Test
https://doi.org/10.1093/ehjci/ehaa946.0949Test